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Abstract: 
To assess the efficacy and safety of sodium-glucose co-transporter 2 (SGLT2) inhibitors 
plus dipeptidyl peptidase-4 (DPP-4) inhibitor in patients with type 2 diabetes mellitus 
(T2DM), we performed a systematic review and meta-analysis of 14 randomized 
controlled trials (RCTs) involving 4,828 patients. Compared with DPP-4 inhibitor, SGLT2 
inhibitor/DPP-4 inhibitor combination therapy was significantly associated with a 
decrease in glycemic control [HbA1c: -0.71%, fasting plasma glucose (FPG): -25.62 
mg/dL, postprandial plasma glucose: -44.00 mg/dL], body weight (-2.05 kg), and systolic 
blood pressure (-5.90 mmHg), but an increase in total cholesterol (TC) of 3.24%, 
high-density lipoprotein of 6.15%, and low-density lipoprotein of 2.55%. Adding DPP-4 
inhibitor to SGLT2 inhibitor could reduce HbA1c by -0.31%, FPG by -8.94 mg/dL, TC by 
-1.48%, and triglycerides by -3.25%. Interestingly, low doses of SGLT2 inhibitor in the 
combination has similar or even better efficacy on some aspects than high doses. Similar 
adverse events were observed for the combination therapy except for genital infection 
versus DPP-4 inhibitor [Risk ratio (RR): 5.31] and consistent genital infection versus 
SGLT2 inhibitor (RR: 0.61). Further studies are warranted to confirm these results. 
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1 Introduction 
Owing to the progressive nature of type 2 diabetes mellitus (T2DM), combination therapy 
is often required to achieve target glucose-lowering efficacy [1]. Recently, combination of 
sodium glucose co-transporter 2 (SGLT2) inhibitor plus dipeptidyl peptidase-4 (DPP-4) 
inhibitor (SGLT2 inhibitor/DPP-4 inhibitor combination therapy) has been raised due to 
their complementary effect in pharmacology: adding DPP-4 inhibitors to SGLT2 
inhibitors could suppress the production of endogenous glucose secondary to excess 
excretion of glucose from urine because they can inhibit glucagon and simulate insulin 
secretion [2,3]. Simultaneously, SGLT2 inhibitors have been shown to enhance the effect 
of DPP-4 inhibitor through improving beta-cell function and insulin sensitivity [4]. 
To qualitatively assess the efficacy and safety of SGLT2 inhibitor/DPP-4 inhibitor 
combination therapy versus SGLT2 inhibitor or DPP-4 inhibitor among the patients with 
T2DM, we performed this systematic review and meta-analysis of available randomized 
controlled trials (RCTs) to provide evidence for clinical use of this combination therapy. 
2 Materials and methods 
Available electronic databases from inception to June 14, 2017 were searched using 
relevant search terms (Table S1) to identify RCTs that reported the efficacy and/or safety 
of SGLT2 inhibitor/DPP-4 inhibitor combination therapy and followed up for at least 12 
weeks. Two reviewers independently performed the study selection, data extraction and 
This article is protected by copyright. All rights reserved.
  
 
quality assessment. Weighted mean difference (WMD) for continuous data and risk ratio 
(RR) for dichotomous data with 95% confidential intervals (CI) were calculated by 
STATA Version 13.0 and Review Manager 5.3 using random effect model. Details about 
the materials and methods were presented in the appendix. 
3 Results 
Fourteen studies involving 4,828 patients were included in this meta-analysis (Figure 1). 
Basic characteristics of included studies and participants were presented in Table S2. Risk 
of bias of included RCTs was summarized in Figure S1. 
3.1 Efficacy outcomes 
Compared with DPP-4 inhibitor, the combination therapy was significantly associated 
with a reduction in HbA1c (WMD, -0.71%; 95% CI, -0.80% to -0.61%), body weight 
(WMD, -2.05 kg; 95% CI, -2.40kg to -1.69 kg), fasting plasma glucose (FPG, WMD, 
-25.62 mg/dL, 95% CI, -39.38 mg/dL to -11.86 mg/dL), postprandial plasma glucose 
(PPG, WMD, -44.00 mg/dL, 95% CI, -53.70 mg/dL to -34.30 mg/dL), and systolic blood 
pressure (SBP, WMD, -5.90 mmHg, 95% CI, -8.85 mmHg to -2.95 mmHg) with a 
statistically significant increase in total cholesterol (TC, WMD, 3.24%; 95% CI, 1.89% to 
4.59%), high-density lipoprotein cholesterol (HDL-C, WMD, 6.15%; 95% CI, 3.97% to 
8.34%), and low-density lipoprotein cholesterol (LDL-C, WMD, 2.55%; 95% CI, 1.78% 
to 3.32%) (Table 1). In the subgroup analysis of triglycerides (TG), combination therapy 
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was associated with an increase in the naïve treatment group (WMD, 7.02%; 95% CI, 
5.90% to 8.14%), but a reduction in metformin group (WMD, -4.08%; 95% CI, -5.68% to 
-2.48%) (Table S3). There is low to high heterogeneity among included studies (I2 range 
from 8.4% to 99.2%). 
Compared with SGLT2 inhibitor, the combination therapy could further reduce HbA1c 
(WMD, -0.31%; 95% CI, -0.38% to -0.24%) , FPG (WMD, -8.94 mg/dL; 95% CI, -11.93 
mg/dL to -5.95 mg/dL), TC (WMD, -1.48%; 95% CI, -2.89% to -0.07%), and TG 
(WMD,-3.25%; 95% CI, -4.66% to -1.85%). The heterogeneity ranged from 3.4% to 97.2% 
(Table 1). 
When compared with low doses of SGLT2 inhibitors in the combination therapy, high 
doses of SGLT2 inhibitor were significantly associated with less reduction in body weight 
(WMD, 0.11 kg; 95% CI, 0.01 kg to 0.21 kg) and DBP (WMD, 0.79 mmHg; 95% CI, 
0.54 mmHg to 1.04 mmHg). More increase in TC (WMD, 2.43%; 95% CI, 1.78% to 
3.07%) and LDL-C (WMD, 3.13%; 95% CI, 1.28% to 4.99%) was observed in the high 
dose group than low dose group. No significant differences were detected among other 
efficacy outcomes (Table1). 
The subgroup analysis indicated similar efficacy regardless of background treatment 
(Table S3-S5). No evidence of publication bias was observed except for FPG between 
combination therapy and DPP-4 inhibitor (Egger’s test, P =0.001; Begg’s test, P =0.902) 
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(Table S6). 
3.2 Safety outcomes 
Compared with DPP-4 inhibitor, combination therapy was significantly associated with 
increased risk of genital infections (RR, 5.31; 95% CI, 1.39 to 20.32; I2 = 40.2%) (Table 
1). Meanwhile, the combination therapy seemed to be associated with lower risk of 
consistent genital infections (RR, 0.61; 95% CI 0.39 to 0.96; I2 = 0.0%) than SGLT2 
inhibitor (Table 1). However, no significant difference was observed in treatment-naïve 
subgroup based on one RCT (RR 0.92; 95% CI 0.43 to 1.97) (Table S4). 
There was no other significant difference on adverse events including hypoglycemia 
(definitions seen in Table S7) between combination therapy and monotherapy, or between 
low and high doses of SGLT2 inhibitor in combination therapy in primary (Table 1) or 
subgroup meta-analysis (Table S3-S5).  
Discussion  
Our meta-analysis of RCTs found that SGLT2 inhibitor/DPP-4 inhibitor combination 
therapy could achieve several aspects of benefits as compared with monotherapy of 
SGLT2 inhibitor or DPP-4 inhibitor. Additionally, this combination might increase TC, 
HDL-C and LDL-C when comparing with DPP-4 inhibitor. Low doses of SGLT2 
inhibitor in the combination therapy even have advantages over high doses in body weight, 
DBP, LDL-C and TC with similar adverse events. 
This article is protected by copyright. All rights reserved.
  
 
Our meta-analysis results demonstrated that adding SGLT2 inhibitor to DPP-4 inhibitor 
could not only further enhance glucose control by reducing HbA1c, FPG and PPG, but 
also compensate the defect of DPP-4 inhibitor on weight loss and blood pressure [5,6]. 
However, the combination therapy has brought about more genital infections. Even 
though the increased genital effect of SGLT2 inhibitor has already been demonstrated [7], 
the combination effect should be further explored. Furthermore, we also observed a 
significant increase in percentage change of fasting lipids except for TG among the 
patients taking combination therapy. In hamsters of diet-induced dyslipidemia [8], 
empagliflozin could increase the activity of 3-hydroxy-3-methylglutaryl-CoA reductase 
and total cholesterol hepatic levels by 31% and 10%, respectively, and decrease hepatic 
LDL receptor protein expression by 20%. HDL-C, which has cardiovascular protective 
effect, was also increased in clinical trials [9] as well as our meta-analysis. However, the 
impact of increased fasting lipids on cardiovascular events in those patients remains 
unclear. 
Compared with SGLT2 inhibitor, this combination therapy also has beneficial efficacy on 
HbA1c, FPG, TC and TG. Similar to previous review [10], our meta-analysis indicated 
that DPP-4 inhibitor/SGLT2 inhibitors combination therapy was associated with lower 
risk of consistent genital infection. Though the underlying mechanism about SGLT2 
inhibitor-related genital infections was still unknown, pharmacologically-induced 
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glucosuria may play a potential role by impairing host defense and/or increasing aldose 
reductase activity [11,12]. It is logical to hypothesize that the reduction of consistent 
genital infection risk of the combination therapy might be caused by relief of glucosuria 
through exerting glucose-lowering effect from another approach when adding DPP-4 
inhibitors to SGLT2 inhibitors, but more evidence is needed to confirm it. 
Though the clinical impact was still unknown, our meta-analysis showed that low doses 
of SGLT2 inhibitor in the combination was associated slightly but significantly more 
reduction in body weight and DBP, and less increase in TC and LDL-C. Low doses of 
SGLT2 inhibitor might be a better choice for clinical use of combination therapy.  
Currently, both SGLT2 inhibitor and DDP-4 inhibitor are recommended as second- or 
third-line treatment options to add to other oral antidiabetic drugs [1]. Our subgroup 
meta-analysis indicated that SGLT2 inhibitor/DPP-4 inhibitor combination therapy could 
provide adequate efficacy without increasing adverse events for patients with naïve 
treatment or metformin. This suggested that the combination strategy could be used for a 
wide range of patients at different stages such as patients with inadequate glycemic 
control by metformin, or that with initial treatment but intolerant of metformin. 
To our knowledge, this is the first meta-analysis performed to compare the efficacy and 
safety profile of combination of SGLT2 inhibitor and DPP-4 inhibitor. Comprehensive 
search strategies were made to avoid selection bias. Meanwhile, the rigorous inclusion 
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criteria ensured the internal validity of these meta-analysis results. We compared not only 
the combination versus SGLT2 inhibitor or DPP-4 inhibitor, but also the suitable doses of 
SGLT2 inhibitors in the combination strategies. Furthermore, subgroup meta-analysis was 
performed to explore the clinical application of this combination.  
Meanwhile, we acknowledged the following limitations. The major limitation of this 
meta-analysis was the limited number of included studies. Even though we had made 
comprehensive research based on eligible databases, only 14 RCTs were finally included, 
and there were even less number of RCTs for subgroup analysis. Secondly, there were 
significant heterogeneity among studies for specific comparisons, such as combination 
therapy versus DPP-4 inhibitor on FPG and that versus SGLT2 inhibitor on body weight. 
Although subgroup meta-analysis was performed, the heterogeneity was still too high for 
us to make confirmative conclusions. 
In conclusion, compared with monotherapy, SGLT2 inhibitor/DPP-4 inhibitor 
combination therapy could achieve additional efficacious effects for patients with 
treatment-naïve or metformin treatment. In addition, this combination therapy might be 
associated with higher risk of genital infections and increased level of TC, HDL-C and 
LDL-C than DPP-4 inhibitor. Low doses of SGLT2 inhibitor might be considered with 
priority when combination therapy is needed. Further studies are warranted to confirm 
these conclusions. 
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Figure legends： 
Figure 1. PRISMA flow chart of the identification of eligible trials  
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Table 1. Summary of meta-analysis results on efficacy and safety outcomes.  
 
SGLT2 inhibitor + DPP-4 inhibitor versus 
DPP-4 inhibitor 
SGLT2 inhibitor + DPP-4 inhibitor versus 
SGLT2 inhibitor 
SGLT2 inhibitor + DPP-4 inhibitor (high 
doses versus low doses)# 
Efficacy 
outcomes n N WMD (95% CI) 
I2 
(%) n N WMD (95% CI) 
I2 
(%) n N WMD (95% CI) I2 (%) 
HbA1c (%) 8 2522 -0.71 (-0.80, -0.61)* 8.4  
7 2648 -0.31 (-0.38, -0.24)* 3.4 
6 1088 0.06 (-0.08, 0.19) 64.1 
Body weight 
(kg) 6 1800 -2.05 (-2.40, -1.69)* 41.9 
4 1349 -0.36 (-1.91, 1.19) 97.1 
4 596 0.11 (0.01, 0.21)* 0.0 
FPG (mg/dL) 8 2511 -25.62 (-39.38, -11.86)* 96.9 
7 2627 -8.94 (-11.93, -5.95)* 35.8 
5 991 0.19 (-3.67, 4.04) 97.4 
PPG (mg/dL) 1 301 -44.00 (-53.70, -34.30)* -- 
1 298 -9.00 (-18.65, 0.65) -- 
0 0 -- -- 
SBP (mmHg) 1 213 -5.90 (-8.85, -2.95)* -- 
3 991 -0.04 (-1.57, 1.49) 0.0 
2 284 0.69 (-0.27, 1.65) 7.7 
DBP (mmHg) 0 0 -- -- 
3 991 -0.26 (-1.25, 0.72) 0.0 
2 284 0.79 (0.54, 1.04)* 0.0 
TC (%) 5 1761 3.24 (1.89, 4.59)* 96.9 
6 2052 -1.48 (-2.89, -0.07)* 97.3  
4 824 2.43 (1.78, 3.07)* 84.4  
HDL-c (%) 6 1974 6.15 (3.97, 8.34)* 99.2 
7 2576 -0.46 (-2.07, 1.16) 52.2  
5 969 -1.58 (-3.85, 0.68) 34.8  
LDL-c (%) 6 1974 2.55 (1.78, 3.32)* 66.6 
7 2576 -0.53 (-2.17, 1.10) 90.9  
5 969 3.13 (1.28, 4.99)* 93.0  
TG (%) 6 1974 -2.48 (-7.30, 2.35) 98.5 
7 2575 -3.25 (-4.66, -1.85)* 62.6  
5 969 -1.66 (-5.64, 2.32) 95.6  
Safety 
outcomes n E/N RR (95% CI) 
I2 
(%) n E/N RR (95% CI) 
I2 
(%) n E/N RR (95% CI) I2 (%) 
Overall adverse 
events 
8 1628/2616 0.98 (0.90, 1.06) 44.5 7 1844/2764 1.01 (0.96, 1.07) 9.9 
6 839/1150 1.00 (0.94, 1.06) 0.0 
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Serious adverse 
events 
8 116/2616 0.84 (0.55, 1.30) 15.7 7 126/2764 0.85 (0.60, 1.21) 0.0  
5 57/1047 0.72 (0.43, 1.20) 0.0 
Hypoglycemia 
8 55/2616 1.07 (0.62, 1.85) 0.0  7 55/2764 0.82 (0.46, 1.46) 0.0  
6 20/1150 1.47 (0.60, 3.59) 0.0 
Severe 
hypoglycemia 
8 3/2616 1.19 (0.15, 9.63) 0.0  7 1/2764 0.33 (0.01, 8.10) -- 
6 1/1150 3.05 (0.13, 74.17) -- 
Drug-related 
adverse events 
5 172/1490 1.21 (0.89, 1.64) 0.0  5 382/2091 0.91 (0.75, 1.10) 0.0  
5 167/1047 1.20 (0.83, 1.72) 37.7 
Adverse events 
leading to 
discontinuation 
8 67/2616 1.23 (0.66, 2.28) 18.6 7 88/2764 0.86 (0.55, 1.34) 0.0  
5 37/1047 0.97 (0.52, 1.84) 0.0 
Consistent 
urinary tract 
infections 
4 148/1587 0.92 (0.64, 1.32) 21.5 4 182/1566 1.03 (0.78, 1.35) 0.0  
4 83/902 0.80 (0.52, 1.21) 1.5 
Consistent 
genital 
infections 
3 39/1136 1.63 (0.78, 3.39) 0.0  4 78/1566 0.61 (0.39, 0.96)* 0.0  
4 32/902 1.17 (0.45, 3.05) 34.6 
Urinary tract 
infections 
8 168/2616 0.95 (0.67, 1.34) 12.9 5 157/2286 1.08 (0.66, 1.75) 50.2 
4 74/908 0.82 (0.53, 1.28) 0 
Genital 
infections 
4 43/1342 5.31 (1.39, 20.32)* 40.2 3 45/1198 0.44 (0.16, 1.23) 11.0  
1 4/145 0.32 (0.03, 3.00) -- 
ketoacidosis 
3 0/686 -- -- 3 0/1003 -- -- 
2 0/367 -- -- 
Abbreviations: SGLT2 inhibitor, sodium glucose cotransporter 2 inhibitors; DPP-4 inhibitor, dipeptidyl peptidase inhibitors; WMD, weighted 
mean difference; CI, confidence interval; RR, risk ratio; FPG, fasting plasma glucose; PPG, postprandial glucose; SBP, systolic blood pressure; 
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DBP, diastolic blood pressure; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, 
triglycerides. 
* Results with statistical differences between comparisons. 
# Low dose of SGLT2 inhibitor refer to canagliflozin 100 mg, dapagliflozin 5 mg and empagliflozin 10 mg, high dose of SGLT2 inhibitor refer 
to canagliflozin 200/300 mg, dapagliflozin 10 mg, and empagliflozin 25 mg 
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Figure 1. 
 
Citations retrieved from electronic databases (n=2,777)  
• PubMed (n=541)  
• Cochrane Library (n=829) 
• Embase (n=1,407)  
• Citations excluded for duplication (n=1,022 ) 
• Citations excluded after title and abstract 
evaluations (n=1,721) 
Full texts of potential studies retrieved for further 
evaluations (n=34) 
Studies excluded according to inclusion criteria 
(n=20) 
• Conference abstracts (n=11) 
• Duplications with the same samples (n=1) 
• No reporting of our interested events (n=6) 
• Follow-up periods of less than 12 weeks (n=2) 
Studies eligible for meta-analysis 
(n= 14) 
Id
en
ti
fi
ca
ti
on
 
Sc
re
en
in
g 
E
lig
ib
ili
ty
 
In
cl
ud
ed
 
This article is protected by copyright. All rights reserved.
